Expression of Long Non-Coding RNA H19 and miR-675 in Patients with Colorectal Cancer and Ulcerative Colitis

ORIGINAL ARTICLE
Rania Sobhy Abu Taleb, Olfat Shaker, Ahmed Khairy, Dalia A. Gaber

 
For citation: Abu Taleb RS, Shaker O, Khairy A, Gaber DA. Expression of Long Non-Coding RNA H19 and miR-675 in Patients with Colorectal Cancer and Ulcerative Colitis. International Journal of Biomedicine. 2024;14(4):575-582. doi:10.21103/Article14(4)_OA6
 
Originally published December 5, 2024
 

Abstract: 

Background: Colorectal cancer (CRC), which has a high mortality rate, is one of the most common malignancies. It is a growing public health problem that recently encompasses the younger age group. Inflammatory bowel disease (IBD), like (UC), is a risk factor for CRC. The aim of this study was to test the expression of microRNA-675 (miR-675) and long noncoding RNA H19 (H19) for their diagnostic and prognostic potential in CRC and UC.
Methods and Results: This prospective cross-sectional study included 60 patients diagnosed with CRC, 60 patients with UC, and 30 healthy subjects as controls. The real-time RT-PCR technique quantified the expressions of the non-coding RNAs (ncRNAs) miR-675 and lncH19. The biochemical and radiological findings were assessed and correlated with the expression of the genetic biomarkers.
H19 showed high expression in both CRC and UC groups, which is significantly different from the control group. There was a significantly enhanced expression of H19 in CRC, compared to the UC group. Increased H19 expression was detected in the caecum and ascending colonic lesions, with a significant difference from flexures and transverse colon (P=0.010), and recto-sigmoid colon (P=0.05). Although miR-675 showed downregulation in both UC and CRC groups, it revealed a higher expression in CRC when compared to the UC group.
Conclusion: Based on our findings, we can conclude that H19 can be a potential noninvasive biomarker for the diagnosis of UC and early detection of CRC.

Keywords: 
lncH19 • miR-675 • colorectal cancer • ulcerative colitis
References: 
  1. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021 Oct;14(10):101174. doi: 10.1016/j.tranon.2021.101174. Epub 2021 Jul 6. PMID: 34243011; PMCID: PMC8273208.
  2. Zhang Y, Devocelle A, Desterke C, de Souza LEB, Hadadi É, Acloque H, Foudi A, Xiang Y, Ballesta A, Chang Y, Giron-Michel J. BMAL1 Knockdown Leans Epithelial-Mesenchymal Balance toward Epithelial Properties and Decreases the Chemoresistance of Colon Carcinoma Cells. Int J Mol Sci. 2021 May 16;22(10):5247. doi: 10.3390/ijms22105247. PMID: 34065633; PMCID: PMC8157026.
  3. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci. 2017 Jan 19;18(1):197. doi: 10.3390/ijms18010197. PMID: 28106826; PMCID: PMC5297828.
  4. Abdulla M. Management of Metastatic unresectable disease of colorectal cancer origin (Part 1: cytotoxic therapy). Res in Oncol. 2013;1(3-4):59-63.
  5. Vukobrat-Bijedic Z, Husic-Selimovic A, Sofic A, Bijedic N, Bjelogrlic I, Gogov B, Mehmedovic A. Cancer Antigens (CEA and CA 19-9) as Markers of Advanced Stage of Colorectal Carcinoma. Med Arch. 2013 Dec;67(6):397-401. doi: 10.5455/medarh.2013.67.397-401. Epub 2013 Dec 28. PMID: 25568506; PMCID: PMC4272469.
  6. Mostafa E F, Metwally A, Hussein S A. Inflammatory Bowel Diseases Prevalence in Patients Underwent Colonoscopy in Zagazig University Hospitals. Afro-Egypt J Infect Endem Dis. 2018; 8(2): 81-87. Doi: 10.21608/aeji.2018.8740.
  7. Porter RJ, Kalla R, Ho GT. Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Res. 2020 Apr 24;9:F1000 Faculty Rev-294. doi: 10.12688/f1000research.20805.1. PMID: 32399194; PMCID: PMC7194476.
  8. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 Mar;114(3):384-413. doi: 10.14309/ajg.0000000000000152. PMID: 30840605.
  9. Choi CR, Bakir IA, Hart AL, Graham TA. Clonal evolution of colorectal cancer in IBD. Nat Rev Gastroenterol Hepatol. 2017 Apr;14(4):218-229. doi: 10.1038/nrgastro.2017.1. Epub 2017 Feb 8. PMID: 28174420.
  10. Yang X, Lou Y, Wang M, Liu C, Liu Y, Huang W. miR‑675 promotes colorectal cancer cell growth dependent on tumor suppressor DMTF1. Mol Med Rep. 2019 Mar;19(3):1481-1490. doi: 10.3892/mmr.2018.9780. Epub 2018 Dec 20. PMID: 30592263; PMCID: PMC6390018.
  11. Yan J, Zhang Y, She Q, Li X, Peng L, Wang X, Liu S, Shen X, Zhang W, Dong Y, Lu J, Zhang G. Long Noncoding RNA H19/miR-675 Axis Promotes Gastric Cancer via FADD/Caspase 8/Caspase 3 Signaling Pathway. Cell Physiol Biochem. 2017;42(6):2364-2376. doi: 10.1159/000480028. Epub 2017 Aug 18. PMID: 28848149.
  12. Li H, Li J, Jia S, Wu M, An J, Zheng Q, Zhang W, Lu D. miR675 upregulates long noncoding RNA H19 through activating EGR1 in human liver cancer. Oncotarget. 2015 Oct 13;6(31):31958-84. doi: 10.18632/oncotarget.5579. PMID: 26376677; PMCID: PMC4741653.
  13. Wang J, Zhao YC, Lu YD, Ma CP. Integrated bioinformatics analyses identify dysregulated miRNAs in lung cancer. Eur Rev Med Pharmacol Sci. 2014 Aug;18(16):2270-4. PMID: 25219825.
  14. Zhang Y, Huang W, Yuan Y, Li J, Wu J, Yu J, He Y, Wei Z, Zhang C. Long non-coding RNA H19 promotes colorectal cancer metastasis via binding to hnRNPA2B1. J Exp Clin Cancer Res. 2020 Jul 22;39(1):141. doi: 10.1186/s13046-020-01619-6. Erratum in: J Exp Clin Cancer Res. 2021 Mar 23;40(1):111. doi: 10.1186/s13046-021-01911-z. PMID: 32698890; PMCID: PMC7412843.
  15. Ti Tili E, Michaille JJ, Piurowski V, Rigot B, Croce CM. MicroRNAs in intestinal barrier function, inflammatory bowel disease and related cancers-their effects and therapeutic potentials. Curr Opin Pharmacol. 2017 Dec;37:142-150. doi: 10.1016/j.coph.2017.10.010. Epub 2017 Nov 15. PMID: 29154194; PMCID: PMC5938753.
  16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 Dec;25(4):402-8. doi: 10.1006/meth.2001.1262. PMID: 11846609.
  17. Kothari C R. Research methodology methods and techniques, 2nd ed New Age International Publishers. New Delhi, India; 2004.
  18. Ahadi A. The significance of microRNA deregulation in colorectal cancer development and the clinical uses as a diagnostic and prognostic biomarker and therapeutic agent. Noncoding RNA Res. 2020 Aug 23;5(3):125-134. doi: 10.1016/j.ncrna.2020.08.003. PMID: 32954092; PMCID: PMC7476809.
  19. Li J, Huang L, Zhao H, Yan Y, Lu J. The Role of Interleukins in Colorectal Cancer. Int J Biol Sci. 2020 Jun 14;16(13):2323-2339. doi: 10.7150/ijbs.46651. PMID: 32760201; PMCID: PMC7378639.
  20. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0. Epub 2017 Oct 16. Erratum in: Lancet. 2020 Oct 3;396(10256):e56. doi: 10.1016/S0140-6736(20)32028-6. PMID: 29050646.
  21. Zhang L, Zhou Y, Huang T, Cheng AS, Yu J, Kang W, To KF. The Interplay of LncRNA-H19 and Its Binding Partners in Physiological Process and Gastric Carcinogenesis. Int J Mol Sci. 2017 Feb 20;18(2):450. doi: 10.3390/ijms18020450. PMID: 28230721; PMCID: PMC5343984.
  22. Sørensen CG, Karlsson WK, Pommergaard HC, Burcharth J, Rosenberg J. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence - A systematic review. Int J Surg. 2016 Jan;25:134-44. doi: 10.1016/j.ijsu.2015.11.065. Epub 2015 Dec 15. PMID: 26700203.
  23. Chew MH, Koh PK, Ng KH, Eu KW. Improved survival in an Asian cohort of young colorectal cancer patients: an analysis of 523 patients from a single institution. Int J Colorectal Dis. 2009 Sep;24(9):1075-83. doi: 10.1007/s00384-009-0701-7. Epub 2009 Apr 23. PMID: 19387661.
  24. González-Senac NM, Mayordomo-Cava J, Macías-Valle A, Aldama-Marín P, Majuelos González S, Cruz Arnés ML, Jiménez-Gómez LM, Vidán-Astiz MT, Serra-Rexach JA. Colorectal Cancer in Elderly Patients with Surgical Indication: State of the Art, Current Management, Role of Frailty and Benefits of a Geriatric Liaison. Int J Environ Res Public Health. 2021 Jun 4;18(11):6072. doi: 10.3390/ijerph18116072. PMID: 34199923; PMCID: PMC8200127.
  25. El- Haddad S, Abdel Hady I, Sakr A, El-nahas T, Rashad A.  Epidemiological Evaluation Focusing on Prognostic Impact of Young Age in Egyptian Patients with Colorectal Cancer, NEMROCK Experience Res Oncol. 2014;10(1-2): 6-11. doi: 10.21608/resoncol.2014.888
  26. Kathpalia P, Sontag S. Age at IBD Diagnosis Does Not Impact Long-term Outcomes: 1785. Am J Gastroenterol. 2013; 108: S538-S539.
  27. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017 Apr 29;389(10080):1756-1770. doi: 10.1016/S0140-6736(16)32126-2. Epub 2016 Dec 1. PMID: 27914657; PMCID: PMC6487890.
  28. Kim SE, Paik HY, Yoon H, Lee JE, Kim N, Sung MK. Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol. 2015 May 7;21(17):5167-75. doi: 10.3748/wjg.v21.i17.5167. PMID: 25954090; PMCID: PMC4419057.
  29. Matin F, Batra J. Profiling MicroRNA Markers in Plasma: Looking into Better Approaches and Recommendations. Methods Mol Biol. 2019;2054:93-103. doi: 10.1007/978-1-4939-9769-5_5. PMID: 31482449.
  30. He D, Wang J, Zhang C, Shan B, Deng X, Li B, Zhou Y, Chen W, Hong J, Gao Y, Chen Z, Duan C. Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer. Mol Cancer. 2015 Apr 1;14:73. doi: 10.1186/s12943-015-0342-0. PMID: 25889562; PMCID: PMC4392735.
  31. Ren J, Fu J, Ma T, Yan B, Gao R, An Z, Wang D. LncRNA H19-elevated LIN28B promotes lung cancer progression through sequestering miR-196b. Cell Cycle. 2018;17(11):1372-1380. doi: 10.1080/15384101.2018.1482137. Epub 2018 Jul 23. PMID: 29950144; PMCID: PMC6110585.
  32. Chen SW, Zhu J, Ma J, Zhang JL, Zuo S, Chen GW, Wang X, Pan YS, Liu YC, Wang PY. Overexpression of long non-coding RNA H19 is associated with unfavorable prognosis in patients with colorectal cancer and increased proliferation and migration in colon cancer cells. Oncol Lett. 2017 Aug;14(2):2446-2452. doi: 10.3892/ol.2017.6390. Epub 2017 Jun 15. PMID: 28781681; PMCID: PMC5530222.
  33. Han D, Gao X, Wang M, Qiao Y, Xu Y, Yang J, Dong N, He J, Sun Q, Lv G, Xu C, Tao J, Ma N. Long noncoding RNA H19 indicates a poor prognosis of colorectal cancer and promotes tumor growth by recruiting and binding to eIF4A3. Oncotarget. 2016 Apr 19;7(16):22159-73. doi: 10.18632/oncotarget.8063. PMID: 26989025; PMCID: PMC5008352.
  34. Ismail DM, Shaker OG, Kandeil MA, Hussein RM. Gene Expression of the Circulating Long Noncoding RNA H19 and HOTAIR in Egyptian Colorectal Cancer Patients. Genet Test Mol Biomarkers. 2019 Sep;23(9):671-680. doi: 10.1089/gtmb.2019.0066. Epub 2019 Aug 21. PMID: 31433231.
  35. Matouk IJ, Halle D, Raveh E, Gilon M, Sorin V, Hochberg A. The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision. Oncotarget. 2016 Jan 26;7(4):3748-65. doi: 10.18632/oncotarget.6387. PMID: 26623562; PMCID: PMC4826167.
  36. Ma L, Tian X, Guo H, Zhang Z, Du C, Wang F, Xie X, Gao H, Zhuang Y, Kornmann M, Gao H, Yang Y. Long noncoding RNA H19 derived miR-675 regulates cell proliferation by down-regulating E2F-1 in human pancreatic ductal adenocarcinoma. J Cancer. 2018 Jan 1;9(2):389-399. doi: 10.7150/jca.21347. PMID: 29344285; PMCID: PMC5771346.
  37. Zou T., Jaladanki S.K., Liu L., Xiao L., Chung H.K., Wang J.Y., Xu Y., Gorospe M., Wang J.Y. H19 long noncoding RNA regulates intestinal epithelial barrier function via microRNA 675 by interacting with RNAbinding protein HuR. Mol Cell Biol. 2016;36:1332–1341. doi: 10.1128/MCB.01030-15.
  38. Lin L, Zhou G, Chen P, Wang Y, Han J, Chen M, He Y, Zhang S. Which long noncoding RNAs and circular RNAs contribute to inflammatory bowel disease? Cell Death Dis. 2020 Jun 15;11(6):456. doi: 10.1038/s41419-020-2657-z. PMID: 32541691; PMCID: PMC7295799.
  39. Schneider C, Bodmer M, Jick SS, Meier CR. Colorectal cancer and markers of anemia. Eur J Cancer Prev. 2018 Nov;27(6):530-538. doi: 10.1097/CEJ.0000000000000397. PMID: 28692587.
  40. Zhu X, Cao Y, Lu P, Kang Y, Lin Z, Hao T, Song Y. Evaluation of platelet indices as diagnostic biomarkers for colorectal cancer. Sci Rep. 2018 Aug 7;8(1):11814. doi: 10.1038/s41598-018-29293-x. PMID: 30087357; PMCID: PMC6081379.
  41. Chen SW, Zhu J, Ma J, Zhang JL, Zuo S, Chen GW, Wang X, Pan YS, Liu YC, Wang PY. Overexpression of long non-coding RNA H19 is associated with unfavorable prognosis in patients with colorectal cancer and increased proliferation and migration in colon cancer cells. Oncol Lett. 2017 Aug;14(2):2446-2452. doi: 10.3892/ol.2017.6390. Epub 2017 Jun 15. PMID: 28781681; PMCID: PMC5530222.
  42. Rogler G, Vavricka S. Anemia in inflammatory bowel disease: an under-estimated problem? Front Med (Lausanne). 2015 Jan 19;1:58. doi: 10.3389/fmed.2014.00058. PMID: 25646159; PMCID: PMC4298217.
  43. Ananthakrishnan AN, Cheng SC, Cai T, Cagan A, Gainer VS, Szolovits P, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1342-8.e1. doi: 10.1016/j.cgh.2013.12.030. Epub 2014 Jan 7. PMID: 24407106; PMCID: PMC4085150.
  44. Wang A, Jiang Y. Correlation analysis of serum levels of H19 and CRP levels and ulcerative colitis. J Med Biochem. 2023 Aug 25;42(3):420-426. doi: 10.5937/jomb0-41359. PMID: 37814617; PMCID: PMC10560500.
  45. Shaker OG, Safa A, Khairy A, Abozeid NF. Serum long noncoding RNA H19/micro RNA-675-5p axis as a probable diagnostic biomarker in inflammatory bowel disease. Mol Biol Rep. 2023 Nov;50(11):9029-9036. doi: 10.1007/s11033-023-08777-8. Epub 2023 Sep 16. PMID: 37716920; PMCID: PMC10635930.

Download Article
Received September 5, 2024.
Accepted October 20, 2024.
©2024 International Medical Research and Development Corporation.